Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China, has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 therapeutic biologic product, VUM02. This product, derived from human umbilical cord mesenchymal stem cells, is designed to treat systemic sclerosis (SS), also known as scleroderma.
Systemic sclerosis is an autoimmune connective tissue disease that manifests as localized or diffuse fibrosis affecting the skin and internal organs, impacting multiple bodily systems. This includes the gastrointestinal tract, heart, lungs, and kidneys, and it is recognized as a rare disease in China. The absence of approved treatments for this condition globally highlights the significance of VUM02’s potential as a novel therapy. Its inclusion in China’s first batch of rare diseases under the Drug Administration Law ensures priority review status for such innovative preparations. – Flcube.com
